BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is headquartered in Branford, Connecticut. It has clinical partnership with Nektar Therapeutics. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation. The company trades on NASDAQ exchange. The company headquarter is located in Branford, CT. The company was established in the 2017.

TickerBTAI
Long NameBioXcel Therapeutics, Inc.
Short NameBioXcel Therapeutics